Raleigh, NC, Feb 16, 2010 – INC Research ®, Inc., a therapeutically focused contract research organization (CRO) with a process for delivering reliable results, has created an Alliance Partnerships program dedicated to the creation and management of strategic clinical delivery alliances with pharmaceutical and biotechnology customers. Tim Dietlin has been appointed VP, Alliance Development to lead this effort on structuring alliance relationships based on joint strategic objectives rather than service level agreements.
Industry-wide challenges driven by consolidation, regulatory scrutiny and intense cost pressures, as well as unprecedented opportunity in areas like biologics, are forcing the entire industry to think differently about its R&D business model. Drug development companies are now looking for a more sophisticated collection and increased utilization of knowledge. Better internal metrics and business intelligence help identify their internal costs are in order to measure the value of outsourcing companies.
“Drug developers are starting to realize that the traditional role of a preferred CRO provider is not producing the financial, efficiency and quality benefits they had hoped for,” said Alistair Macdonald, executive vice president, Strategic Development at INC Research. “We want to take these relationships to the next level by developing commercial level solutions supported by our excellence in clinical trial execution. Tim brings a wealth of experience in helping clinical development leaders understand how to best manage internal resources and outsourcing partners and how to realize the value of a relationship at all levels."
INC Research’s clinical delivery alliance structures can include complete management of a compound or therapeutic area; management of a specific function or set of critical processes; sharing in the risk and reward of a compound's performance; or acting as the sole source development partner for a customer. The company’s proven experience with process-driven clinical research methods and its popular metrics-based Trusted Process® provides the foundation for successful strategic alliances.
About INC Research® Inc.
INC Research is a therapeutically focused contract research organization with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women’s health trials. The company’s The Trusted Process® methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, North Carolina. For more information please visit www.incresearch.com.
